Home

The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.

The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term.

 

 

 

New-fig

 

 

This video shows the web-based 3D viewer that will be used for pre- and post-processing of In Silico Clinical Trials: